Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Health Ministry Subcommittees Agree to Continue Suspending Recommendation for HPV Vaccines
October 30, 2013
- MHLW Discussing OTC Status for Certain In Vitro Diagnostics
October 30, 2013
- 1st Committee Backs Japan Tobacco’s Hyperphosphatemia Treatment
October 30, 2013
- MHLW Rejects 2 Applicants for Cell-Based Flu Vaccine Subsidy Project
October 29, 2013
- Conclusion of TPP Talks over IP Rights Postponed
October 29, 2013
- Kenporen Calls for Taking 6 APIs Over the Counter
October 29, 2013
- LDP Establishes Study Group on Pharmaceutical Industry Policy; 11 Domestic Drug Makers to Participate
October 28, 2013
- TPP IP Talks Kick Off in Tokyo, Government Task Force to Hold Press Conference on Oct 28
October 25, 2013
- Regulatory Reform Council to Convene Public Discussion on Expansion of “Mixed Healthcare” on November 28
October 25, 2013
- Diovan Panel Should Question 4 Key Figures to Dig into Scandal Further: Expert Member
October 24, 2013
- Lawmakers Concerned over Effects of Diovan Papers on Public Finances for Health Insurance
October 24, 2013
- Probable Price Settlement Rate of Lower 70% Range “Disappointing”: MHLW’s Economic Affairs Head Jo
October 24, 2013
- PFSB Notification Calls for Revisions to Precautions Sections of Package Inserts for Olmesartan and Other Drugs
October 24, 2013
- MOF Demands Hefty Price Cuts for Long-Listed Products, Skeptical about Premium
October 23, 2013
- Govt Task Force Briefs Trade Groups on Tokyo’s Hosting of TPP Interim Talks on IP
October 23, 2013
- Basic Policy Calls for Wider Range of Uninsured Healthcare Services in National Strategic Special Zones
October 23, 2013
- Expert Panel Calls for Measures to Promote Commercialization of Results of Basic Research in Field of Healthcare
October 23, 2013
- DPJ Nagatsuma Requests Summoning Novartis President and Former Employee for Unsworn Diet Testimony
October 22, 2013
- Avastin to Receive Additional Indication for Ovarian Cancer: PAFSC’s Second Committee on Drugs
October 22, 2013
- Vaccine Policy Committee Agrees on Draft of Basic Vaccination Plan
October 22, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…